Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Two Treatment Schemes With Antivipmyn for Snake Bite Envenomation
NCT00639951Phase 4Terminated
- Sponsor
- Instituto Bioclon S.A. de C.V.
- Start
- Jan 2008
- Primary completion
- Jan 2009
- Modality
- Fab Fragments, Blood Coagulation Factors
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Antivipmyn in snakebite envenomation (2 arms), sponsored by Instituto Bioclon S.A. de C.V. Primary endpoint: Resolution of systemic signs and symptoms of snake bite envenomation at 12 hours. Started Jan 2008; status: terminated.
02
Drugs
Antivipmyn
03
Conditions
snakebite envenomation
Beyond the preview
Go deeper on NCT00639951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00639951.